Epi proColon Publications

More Information

Epi proColon® Publications

Year Citation
2017 Song L. and Li Y. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Biomark. Med (doi:10.2217/bmm-2017-0091)
2017 Song L et. Al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep. 2017 Jun 8;7(1):3032. doi: 10.1038/s41598-017-03321-8.
2017 Song L et. al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location Journal of Cancer Research in Clinical Oncology DOI 10.1007/s00432-017-2363-0
2017 deVos T, Molnar B. Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA. J Clin Epigenet. 2017, 3:1. doi: 10.21767/2472-1158.100040
2017 Song, L. et al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J Cancer Res Clin Oncol (2017) 143: 1093. doi:10.1007/s00432-017-2363-0
2017 Inadomi J. Screening for Colorectal Neoplasia. N Engl J Med 2017; 376:149-156
2016 Nian J. et. al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis Clin Transl Gastroenterol. 2017 Jan 19;8(1):e216. doi: 10.1038/ctg.2016.66
2016 Liles E. et. al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. http://dx.doi.org/10.1016/j.ctarc.2016.12.004
2016 Toth K. et. al. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients Pathol Oncol Res. 2016 Dec 30. doi: 10.1007/s12253-016-0174-2
2014 Johnson D et. al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLOS ONE. 9(6):1-8. e98238
2014 Potter N et. al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clinical Chemistry. 60(9):1183-1191
2014 deVos T et al. Blood-based tests for colorectal cancer screening. Clin Lab Int. Oct. 2014:18-20
2014 Pratt V. Are we ready for a blood-based test to detect colon cancer? (editorial). Clinical Chemistry. 60(9):1141-1142
2013 Laudabaum U et. al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated Septin9 DNA vs. current strategies. Cancer Epidemiology, Biomarkers & Prevention. Jun 24. PMID:23796793
2013 Heichman K. Blood-based testing for colorectal cancer screening. Molecular Diagnosis and Therapy. DOI 10.1007/s40291-013-0074-z
2013 Church T et. al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63:317-325. Doi10.1136/gutjnl-2012-304149
2012 Lofton-Day C et. al. Opportunities and limitations of blood-based CRC screening tests. Practical Gastroenterology. 36(7):29-34
2011 Warren J et. al. Septin9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Medicine. 9:133
2010 Payne S et. al. From discovery to the clinic: the novel DNA methylation biomarker mSEPT9 for the detection of colorectal cancer in blood. Epigenomics. 2(4):575–585
2009 deVos T et. al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry. 55(7):1337-1346
2008 Lofton-Day C et. al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry. (54)2:414-423